
Epidemiology of malignant melanoma in Japan: Japan Melanoma Study Group

Japan Skin Cancer Society, Skin Cancer Prognosis Research Committee: Yasuhiro FUJISAWA (University of Tsukuba)




Disease specific survival rate (5 year-DSS) 100 **-**lb →IIb **-**IIIa Tis:100% **8**50 IIc: 67% 25 IIIa: 78% IIIb: 59% IIIc: 43% IV: 17% 8 9


Does clinical classification correlate with survival? survival rate(%) All clinical classification with all stage (n=2833) specific **—**ALM 4 Clinical classification with **-**LMM pathological stage **→**NM 25 SSM (n=2174)**—**Unknown Mucosa 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 Survival (Year)

Factors	Hazard ratio	95%CI	P-value
Clinical classification	(reference:SSM)		
ALM	1.043	0.800~1.359	0.755
NM	1.282	0.951~1.727	0.103
LMM	1.041	0.638~1.697	0.871
T (1~4, continuous var.)	1.857	1.646~2.095	<0.0001
$N (0^3, continuous var.)$	1.282	1.511~1.845	<0.0001
M (0 or 1)	3.350	2.484~4.516	<0.0001

Survival (Years)

Clinical classification does not correlate with survival





	<u> </u>	<u> </u>		
Factors	Hazard ratio	95% CI	<i>P</i> -value	
Clinical classification (Reference:SSM)				
ALM	2.974	1.126~7.854	0.0278	
NM	1.197	0.398~3.592	0.748	
LMM	_	_	_	
(1~4, continuous var.	1.816	1.118~2.950	0.016	
(1or2,continuous var.	1.496	0.656~3.415	0.338	
In Stage IIIa, A	LM correlate	with poor s	urvival	

Multivariate analysis in Stage IIIa

SSM StageIII(n=239) ALM Stage III(n=253) **→**ALM:IIIa -ALM:IIIb **→**ALM:IIIc specific 50 50 **→**SSM:IIIa

25

Survival (Years)

Why ALM Stage IIIa had worse DSS compared with SSM?

- * Background was comparable (age, sex, etc)
- * T1/2/3/4a ratio and average tumor thickness were also comparable
- * N1a:2a radio was higher in ALM (1:0.69 vs 1:0.41) > more **N2a** in ALM
 - >But chi-square test showed no statistical difference (P=0.21) and multivariate analysis showed no correlation between N status and survival in IIIa

* In total, ALM and SSM had similar disease-specific survival >TNM status correlates with survival, not clinical classification * However, Stage IIIa ALM had worse survival compared with SSM >No reasonable explanation

Participating 26 institutes

-SSm:IIIb

-SSM:IIIc

8 9 10 11 12

5 6 7

Asahikawa Medical school 164 pts Dr. Uehara J University of Gifu 80 pts 220 pts Dr. Asai J **Kyoto Medical University** University of Kyushu 244 pts Dr. Uchi H

University of Kumamoto 214 pts Dr. Ihn H, Fukushima S

56 pts Dr. Kishi A

Disease

Toranomon Hospital

Niigata Cancer Center University of Kobe Shizuoka Cancer Center National Cancer Center Saitama Medical University Saitama Medical University, International Medical Center Saitama Cancer Center Sapporo Medical University Occupational Medical University Shinshu Medical University

8 9 10 11 12

286 pts Dr. Takenouchi T Dr. Fujiwara S Dr. Kiyohara Y, Yoshikawa ** Dr. Yamazaki N, Namikawa K 90 pts Dr. Ogata D Dr. Nakamura Y, Teramoto Y 55 pts Dr. Ishikawa M 220 pts Dr. Uhara H, Kato J

67 pts Dr. Hino R

375 pts Dr. Minakawa A

Osaka City University University of Tsukuba University of Tokyo University of Tohoku Nippon Medical University Hamamatsu Medical University Toyama Prefectural Central Hospital University of Fukuoka University of Hokkaido

University of Nagoya

212 pts Dr. Kamo R Fujisawa Y 174 pts Dr. Yamada D Dr. Fujimura T Dr. Hoashi T Dr. Fujiyama T Dr. Hatta N Dr. Shibayama **

61 pts Dr. Furukawa H

280 pts Dr. Yokota K, Urata T